Washington University School of Medicine
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Inclusion Criteria for both Phase Ib and Phase II: * Hormone receptor-positive, HER2-negative metastatic breast cancer. * Measurable or non-measurable but evaluable disease by RECIST v1.1. * Candidate for capecitabine treatment per physician decision. See below phase-specific eligibility criteria for further guidance. * No more than one prior chemotherapy for metastatic disease. * Patient must have received prior endocrine therapy with CDK4/6 inhibitor. * If patient is on denosumab or zoledronic acid prior to enrollment, patient must have been on the regimen for at least 6 months prior to stu…
Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
Standard of care. Will receive zoledronic acid or denosumab.
Standard of care. Will receive zoledronic acid or denosumab.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.